Zacks Research Estimates Neogen’s Q4 Earnings (NASDAQ:NEOG)

Neogen Co. (NASDAQ:NEOG) – Equities research analysts at Zacks Research upped their Q4 2025 EPS estimates for shares of Neogen in a note issued to investors on Tuesday, December 3rd. Zacks Research analyst R. Department now forecasts that the company will earn $0.18 per share for the quarter, up from their previous estimate of $0.17. The consensus estimate for Neogen’s current full-year earnings is $0.50 per share. Zacks Research also issued estimates for Neogen’s FY2026 earnings at $0.61 EPS and FY2027 earnings at $0.75 EPS.

Separately, StockNews.com upgraded shares of Neogen to a “sell” rating in a report on Monday, September 30th.

Neogen Stock Down 0.2 %

Shares of NASDAQ NEOG opened at $13.23 on Thursday. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.79 and a current ratio of 4.41. Neogen has a 12 month low of $11.46 and a 12 month high of $20.89. The firm has a fifty day simple moving average of $14.81 and a two-hundred day simple moving average of $15.62.

Neogen (NASDAQ:NEOG) last issued its quarterly earnings data on Thursday, October 10th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.03). Neogen had a positive return on equity of 2.80% and a negative net margin of 2.58%. The company had revenue of $217.00 million during the quarter, compared to the consensus estimate of $215.05 million. During the same quarter last year, the company posted $0.11 earnings per share. The firm’s revenue for the quarter was down 5.2% compared to the same quarter last year.

Institutional Trading of Neogen

Several institutional investors have recently bought and sold shares of NEOG. Franklin Resources Inc. boosted its holdings in shares of Neogen by 33.9% during the 3rd quarter. Franklin Resources Inc. now owns 923,918 shares of the company’s stock valued at $15,531,000 after acquiring an additional 233,796 shares during the last quarter. Neo Ivy Capital Management purchased a new stake in shares of Neogen during the 3rd quarter valued at about $66,000. Geode Capital Management LLC boosted its holdings in shares of Neogen by 0.4% during the 3rd quarter. Geode Capital Management LLC now owns 5,148,388 shares of the company’s stock valued at $86,559,000 after acquiring an additional 20,387 shares during the last quarter. Barclays PLC boosted its holdings in shares of Neogen by 129.8% during the 3rd quarter. Barclays PLC now owns 366,753 shares of the company’s stock valued at $6,165,000 after acquiring an additional 207,160 shares during the last quarter. Finally, State Street Corp boosted its holdings in shares of Neogen by 3.1% during the 3rd quarter. State Street Corp now owns 7,932,192 shares of the company’s stock valued at $133,340,000 after acquiring an additional 236,762 shares during the last quarter. 96.73% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Neogen

In other Neogen news, CEO John Edward Adent bought 14,500 shares of Neogen stock in a transaction dated Friday, October 11th. The shares were purchased at an average cost of $13.80 per share, with a total value of $200,100.00. Following the transaction, the chief executive officer now directly owns 216,477 shares of the company’s stock, valued at $2,987,382.60. This represents a 7.18 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 1.13% of the company’s stock.

About Neogen

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.